Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9159465 | 1.00 | ADORA2B (0.66) | ADORA2BADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL9158997 | 0.94 | ADORA2B (0.58) | ADORA2BADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL9158983 | 0.94 | ADORA2B (0.58) | ADORA2BADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL6555024 | 0.93 | ADORA2B (0.73) | ADORA2BADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL6555021 | 0.93 | ADORA2B (0.73) | ADORA2BADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL9152046 | 0.92 | ADORA2B (0.68) | ADORA2BADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL9152034 | 0.92 | ADORA2B (0.68) | ADORA2BADORA3ADORA2AADORA1KDM4E | |
| SCHEMBL6553753 | 0.88 | ADORA2B (0.53) | ADORA2BADORA3ADORA2AADORA1PTPN1 | |
| SCHEMBL6553746 | 0.88 | ADORA2B (0.53) | ADORA2BADORA3ADORA2AADORA1PTPN1 | |
| SCHEMBL9153363 | 0.87 | ADORA2B (0.63) | ADORA2BADORA3ADORA2AADORA1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0639055-A1 | METHODS OF TREATING OBESITY WITH PURINE RELATED COMPOUNDS | THE PENN STATE RESEARCH FOUNDATION (US) | 1995-02-22 | — | — | EP | claimed |
| WO-1993021783-A1 | METHODS OF TREATING OBESITY WITH PURINE RELATED COMPOUNDS | THE PENN STATE RESEARCH FOUNDATION (US) | 1993-11-11 | — | — | WO | claimed |
| EP-0203721-B1 | 8-PHENYL XANTHINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-06-10 | — | — | EP | claimed |
| US-4879296-A | BLOCKING ADERNOSINE CELL SURFACE EFFECTS | BURROUGHS WELLCOME CO. (US) | 1989-11-07 | — | — | US | claimed |
| EP-0203721-A2 | 8-Phenyl xanthines | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-12-03 | — | — | EP | claimed |
| EP-0639055-A1 | METHODS OF TREATING OBESITY WITH PURINE RELATED COMPOUNDS | THE PENN STATE RESEARCH FOUNDATION (US) | 1995-02-22 | — | — | EP | disclosed |
| US-5300298-A | Methods of treating obesity with purine related compounds | THE PENNSYLVANIA RESEARCH CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
| WO-1993021783-A1 | METHODS OF TREATING OBESITY WITH PURINE RELATED COMPOUNDS | THE PENN STATE RESEARCH FOUNDATION (US) | 1993-11-11 | — | — | WO | disclosed |
| EP-0203721-B1 | 8-PHENYL XANTHINES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
| US-5017577-A | Using Purine Cinnamic Acids | BURROUGHS WELLCOME CO. (US) | 1991-05-21 | — | — | US | disclosed |
| US-5015647-A | Using Purine Cinnamic Acid Compounds | BURROUGHS WELLCOME CO. (US) | 1991-05-14 | — | — | US | disclosed |
| US-4981857-A | ADENOSINE ANTAGONIST | BURROUGHS WELLCOME CO. (US) | 1991-01-01 | — | — | US | disclosed |
| US-4879296-A | BLOCKING ADERNOSINE CELL SURFACE EFFECTS | BURROUGHS WELLCOME CO. (US) | 1989-11-07 | — | — | US | disclosed |
| EP-0243192-A2 | Antiviral 8-Phenylxanthines | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-10-28 | — | — | EP | disclosed |
| EP-0203721-A2 | 8-Phenyl xanthines | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-12-03 | — | — | EP | disclosed |